Pfizer announced that it has stopped a Phase 3 clinical trail of Lyrica for patients with HIV neuropathy based on an interim analysis of the results. “The results of this study show the complexities of studying pain, particularly in a difficult-to-treat condition such as neuropathic pain associated with HIV neuropathy for which there are no approved medications in the US”, said Steven Romano, MD, Senior VP, Head, Medicines Development Group. READ MORE
Source: Marketwatch